After the Nvidelity comes the Huangover. Jensen Huang joins long list who confused boardroom and bedroom
Astrazeneca makes lupus breakthrough August 29, 2019 Astrazeneca today took a leap forward for lupus patients who have been waiting for decades for a breakthrough, bouncing back from disappointing results last year. The second round of phase three trials for anifrolumab, a new drug, showed positive results on lupus patients, the company said this morning. Read more: Astrazeneca gets boost as good [...]
Astrazeneca gets boost as good news comes in pairs August 28, 2019 Astrazeneca got a double immune boost today as one of its drugs was given orphan status in the US, while trials of a pulmonary medicine showed positive results. The firm said its medicine Fasenra was granted special status as an orphan drug in the US. Orphans are medicines that treat rare diseases. Read more: Astrazeneca [...]
Astrazeneca faces setback in lung cancer trials August 21, 2019 Astrazeneca took a blow this morning as it revealed that trials of a lung cancer drug had not lived up to hopes pinned on it. Patients given Imfinzi with tremelimumab did not show better overall survival rates than those on standard chemotherapy, Astra said this morning. Read more: Heart patients given boost by Astrazeneca drug [...]
Heart patients given boost by Astrazeneca drug trials August 20, 2019 A new Astrazeneca drug might help patients with heart failure, half of whom die within five years of being diagnosed, as the company this morning showed encouraging trial results. The Anglo-Swedish drugmaker said that the third phase of trials of its Farxiga medicine significantly reduced cardiovascular death or prevented heart failure from getting worse. Read [...]
Astrazeneca share price rises as new cancer drugs boost sales July 25, 2019 Shares in Astrazeneca rose more than five per cent this morning after bumper sales of new cancer drugs fuelled a revenue rise in the second quarter. Read more: Astrazeneca promises cash to back up £12m redundancy payments for former staff The FTSE 100 pharmaceutical giant posted a 14 per cent rise in sales to $5.7bn [...]
GSK eyes former Astrazeneca CFO for empty chair July 14, 2019 Drugmaker Glaxosmithkline is set to announce the former finance boss of Astrazeneca as its new chair to oversee the breakup of the business. GSK is preparing to appoint Jonathan Symonds as its new non-executive chair, Sky News reported earlier. Read more: GSK to split as it forms £9.8bn consumer health venture with Pfizer The announcement [...]
Our healthcare system is trapped in an impasse as pharmaceutical firms struggle to fund medical innovations May 1, 2019 The price of technological innovations in health care has once again been brought into focus. Orkambi, a new pharmaceutical treatment for a specific type of cystic fibrosis has not been approved for availability on the NHS because its price is deemed too high. Meanwhile, there is panic at the relentless rise of fatal antibiotic-resistant infections [...]
Nine UK shares that tick all of Warren Buffett’s boxes March 26, 2019 | City Talk By Kyle Caldwell from interactive investor. Looking for equity-based ISA inspiration? We run through the investment checklist of the Berkshire Hathaway chairman to identify UK shares that pass his stockpicking rules. American investor Warren Buffett is to the world of investment what Lionel Messi is to football: the greatest of his generation in the profession [...]
Chinese demand for medicines helps Astrazeneca return to growth February 14, 2019 Strong growth in Chinese demand for new medicines helped Astrazeneca return to growth in 2018, it said today. The figures Product sales grew four per cent in 2018 compared to 2017, to hit $21bn (£16.35bn) in revenue. Fourth quarter revenue grew to $5.77bn, up five per cent year on year. Read more: Bristol-Myers Squibb to [...]
Trade body says hardcore of ‘repeat offenders’ are failing to listen to investor views December 4, 2018 The trade body for UK investment managers has written to 32 companies on the Ftse-all share to register concern after they faced significant shareholder dissent for the last two years. The Investment Association (IA) said it was concerned that these companies had appeared on the public register, which tracks significant shareholder dissent, for the same [...]